 
 |
|
Life Technologies and febit Team to Offer New Solution for Targeted Re-sequencing in Large-scale Genomic Studies
Date: September 28, 2009
Client: febit holding GmbH
Summary: CARLSBAD, CA. (USA), and HEIDELBERG, Germany, September 28, 2009 – febit holding GmbH and Life Technologies Corporation (NASDAQ: LIFE) today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted re-sequencing studies. In addition, febit will expand its Genomic Services Facility at Heidelberg by adding several Applied Biosystems SOLiD™ high-throughput sequencing systems and real-time PCR systems. Applied Biosystems is a brand of Life Technologies. As part of the agreement, febit is a member of both the SOLiD System and TaqMan Service Provider Programs. These programs are intended to provide the scientific community with broad access to a comprehensive solution for genomic research using next-generation sequencing.
|
|
|
|
 |
|
FAME Trial Two-Year Follow-Up Results Demonstrate Continued Reduction in Risk of Death or Heart Attack When Physicians Use St. Jude Medical Fractional Flow Reserve Technology Prior to Implanting Coronary Stents
Date: September 23, 2009
Client: St. Jude Medical, Inc.
Summary: ST. PAUL, Minn.--(BUSINESS WIRE)--Sep. 23, 2009-- St. Jude Medical, Inc. (NYSE:STJ) today announced that the two-year results from the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial demonstrated the durability of the improved outcomes noted at one-year for patients with multivessel coronary artery disease whose treatment was guided by FFR rather than by standard angiography alone. Two-year results demonstrated that the risk of death or myocardial infarction (heart attack) was 34% lower for patients whose treatment was guided by St. Jude Medical’s PressureWire technology prior to coronary stenting.
|
|
|
|
 |
|
Pre-clinical Data Show OrbusNeich’s Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
Date: September 23, 2009
Client: OrbusNeich
Summary: SAN FRANCISCO, Sept. 23, 2009 – OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company’s Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher® sirolimus eluting stent and the XIENCE™ V everolimus eluting stent.
|
|
|
|
 |
|
Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Date: September 23, 2009
Client: Pluristem Therapeutics Inc.
Summary:
HAIFA, Israel--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
|
|
|
|
 |
|
Cohera Medical Receives ISO 13485 Certification: Company Meets International Standards for Design, Development and Manufacturing of Medical Devices
Date: September 22, 2009
Client: Cohera Medical, Inc.
Summary: PITTSBURGH, Sept. 22, 2009 - Cohera Medical, Inc. announced today that it has received certification to the ISO 13485:2003 International Standard for the Design, Development, and Manufacture of Surgical Adhesives. Receipt of the certification allows Cohera Medical to proceed with the CE Mark registration and approval process for TissuGluÒ, the company's novel internal surgical adhesive, upon completion of development for its first indication to optimize healing and prevent fluid accumulation following abdominoplasty procedures.
|
|
|
|
|
|
|
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI
Date: September 22, 2009
Client: OrbusNeich
Summary: SAN FRANCISCO, Sept. 22 /PRNewswire/ -- OrbusNeich announced today that interim data from a prospective registry showed good safety in a broad population of patients that underwent primary percutaneous coronary intervention (PCI) and implantation of the company's Genous Bio-engineered R stent for ST-elevation myocardial infarction (STEMI).
|
|
|
|
|
|
|
Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Date: September 22, 2009
Client: OrbusNeich
Summary: SAN FRANCISCO, Sept. 22 -- OrbusNeich today announced that the final 12-month clinical data from the global e-HEALING clinical study showed that the company's Genous Bio-engineered R stent is safe and effective in real world use, including in the treatment of patients with diabetes mellitus.
|
|
|
|
 |
|
Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances
Date: September 18,2009
Client: Ambrx Inc.
Summary: Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Ambrx Inc. today announced the formation of a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets inmultiple therapeutic areas. The alliance will capitalize on Ambrx's recent breakthroughs in applying its protein medicinal chemistry platform to proteins produced in mammalian cells such as antibodies and antibody-toxin conjugates
|
|
|
|
 |
|
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date: September 18, 2009
Client: Arena Pharmaceuticals, Inc.
Summary: SAN DIEGO, Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today positive, highly significant top-line results from the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial. BLOSSOM confirms the results previously reported for the BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial and completes the lorcaserin Phase 3 pivotal registration program of 7,190 patients evaluated for up to two years. Arena plans to submit a New Drug Application, or NDA, for lorcaserin to the US Food and Drug Administration, or FDA, in December.
|
|
|
|
|
|
|
OrbusNeich’s Genous™ Bio-engineered R stent™ is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports
Date: September 11, 2009
Client: OrbusNeich
Summary: HONG KONG, Sept. 11, 2009 – OrbusNeich’s Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy, according to a paper published online in the International Journal of Cardiology (Int J Cardiol. 2009 Aug 21. [Epub ahead of print]).
|
|
|
|
|
|
|
Pluristem Begins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Date: September 10, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel--Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
|
|
|
|
|
|
|
Pluristem Therapeutics Will Present its Unique Placenta Derived Stem Cell Therapy Approach at Charles River Biotech Symposium
Date: September 9, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that it will present its unique placenta derived stem cell therapy approach and the company's strategy and vision for choosing the placenta as the source for cell therapy, at the Charles River Biotech Symposium on Biotechnology Derived Therapeutics in La Jolla, Calif.
|
|
|
|
 |
|
Helix BioPharma Closes Private Placement
Date: September 8, 2009
Client: Helix BioPharma Corp.
Summary: (Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that it has closed its previously announced private placement of 6,625,000 units at $2.05 per unit.
|
|
|
|
 |
|
Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC25 inhibitor (IRC-083864 or Debio 0931), an anti-cancer agent
Date: September 7, 2009
Client: Debiopharm Group, SA
Summary: Paris (France) and Lausanne (Switzerland), 7 September 2009 – Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen’s first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
|
|
|
|
|
|
|
Helix BioPharma Announces $13.5 Million Private Placement
Date: September 4, 2009
Client: Helix BioPharma Corp.
Summary: (Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at $2.05 per unit, for gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private placement by September 11, 2009.
|
|
|
|
|
|
|
Helix BioPharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date: September 3, 2009
Client: Helix BioPharma Corp.
Summary: (AURORA, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF) today announced that John Docherty, president and chief operating officer, will present at the Rodman and Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York Palace Hotel in New York. Mr. Docherty will provide an overview of the Company’s leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company’s website, www.helixbiopharma.com, on September 9th, 2009.
|
|
|
|
|
|
|
The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
Date:September 3, 2009
Client:Debiopharm Group, SA
Summary:Lausanne, Switzerland, September 3, 2009 - Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the ‘Debiopharm Life Sciences Award’ to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection. Funded by Debiopharm, the ceremony took place at the EPFL (Ecole Polytechnique Fédérale de Lausanne) during the EPFL School of Life Sciences Inaugural Symposium. Dr Quintana-Murci and his institute received a total of CHF 100’000.
|
|
|
|
|
|
|
Helix BioPharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:September 3, 2009
Client:Helix BioPharma Corp.
Summary: AURORA, Ontario, Sept. 3 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that John Docherty, president and chief operating officer, will present at the Rodman and Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York Palace Hotel in New York. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on September 9th, 2009
|
|
|
|
|
|
|
Next-Gen Presents Array of Opportunities -- Researchers Are Finding Myriad Applications for This Rapidly Evolving Technology - Elizabeth Lipp
Date: September 1, 2009
Client: febit
Summary: Next-generation sequencing (NGS) has arrived. “The expansion of users and applications shows no signs of abating,” notes Michael Rhodes, Ph.D., senior manager, SOLiD Sequencing at Applied Biosystems, a division of Life Technologies. “The uptick of transcriptomics applications has been faster than expected. Human genome resequencing projects will increase, and the existing eight published genomes will vastly increase.”
“NGS is an important area right now,” agrees Fred Ernani, Ph.D., product manager at Agilent Technologies. “Scientists look for solid tools and improved workflows. Making tools more efficient is crucial. Many lower throughput systems don’t lend themselves to automation so variability in results needs to be addressed.”
|
|
|
|
|
